India's biotechnology sector is undergoing a remarkable transformation. The country's bioeconomy has expanded from approximately $10 billion in 2014 to over $195 billion in 2025, recording an annual growth of around 17–18 percent. The sector now contributes around 4.8 percent to the national GDP and is steadily moving toward a $300 billion bioeconomy target by 2030.
Within this rapidly expanding ecosystem, peptides in India have emerged as a focal point of research and commercial activity. From academic laboratories to pharmaceutical companies, the demand for high-purity research peptides continues to grow across the country.
The Indian Peptide Market: By the Numbers
The numbers tell a compelling story. The peptide therapeutics market in India generated revenue of USD 1,127.3 million in 2025 and is expected to reach USD 2,649.8 million by 2033, representing a compound annual growth rate of 9.9%. Metabolic disorders were the largest revenue-generating application segment in 2025 and remain the fastest-growing category.
India's peptide CDMO segment, currently worth $80 million and accounting for just 3 percent of the $190 billion global market, is projected to grow at a compound annual rate of 14 percent over the next five years. The Indian peptide supplements and API market is currently valued at USD 450–650 million, with a projected CAGR of 8.0–12.0 percent driven largely by the increasing prevalence of metabolic disorders.
The functional foods and beverages segment is forecast to be the fastest-growing end-use sector, expanding at 18–22 percent CAGR, as major Indian food and beverage companies incorporate bioactive peptides into everyday nutrition products. Domestic production capacity is expected to double by 2030, reaching 600–800 metric tons annually.
What Is Driving the Growth of Peptides in India?
Several factors are fueling the expansion of peptide research and production in India:
Government Support and Policy Initiatives
The BioE3 Policy (Biotechnology for Economy, Environment and Employment) represents a major step towards strengthening bio-based industries and sustainable biomanufacturing. The Research, Development, and Innovation (RDI) Fund with an outlay of ₹1 lakh crore has been established to support biotechnology ventures. BIRAC is facilitating this transformation by building shared infrastructure such as bio foundries, Bio-AI hubs, and advanced biomanufacturing platforms.
Patent Expiries
Patents on blockbuster GLP-1 therapies, including semaglutide, are expiring. The GLP-1 agonist market has grown from 2022 levels to Rs 1,446 crore in MAT February 2026, with steady growth in both unit consumption and market value. This opens significant opportunities for Indian manufacturers and researchers working with peptides in India.
Growing Research Community
India now has over 11,800 biotech startups, powering the country's expanding bioeconomy. The cumulative number of registered biotech startups continues to rise, creating sustained demand for research-grade peptides in India.
Expanding Research Infrastructure
India's research institutions are making significant contributions to peptide science. IIT Jodhpur's Department of Bioscience and Bioengineering has conducted research on engineered neuro-regenerative peptide hydrogels. CSIR-Indian Institute of Chemical Biology in Kolkata and IISER Kolkata are engaged in peptide design and antimicrobial peptide research. IIT Guwahati has conducted research on de novo design of antimicrobial peptides. IIT Delhi's Kusuma School of Biological Sciences has produced research on peptide biologics for cancer and fungal infections. IIT Kanpur has conducted research on crown ether-containing peptides. Granules India has established two advanced Centres of Excellence at IIT Hyderabad, including the Ascelis CoE for Peptide Development and Characterization.
Regulatory Landscape for Peptides in India
In India, the Central Drugs Standard Control Organization (CDSCO) regulates peptides under the Drugs and Cosmetics Act, 1940, and the New Drugs and Clinical Trials Rules, 2019. However, CDSCO frequently applies biologic-like scrutiny based on manufacturing complexity regardless of peptide size, creating regulatory divergence from USFDA logic.
While the USFDA treats chemically synthesized peptides under 40 amino acids as small molecules, CDSCO applies more stringent oversight based on manufacturing complexity rather than peptide length. This creates unique regulatory considerations for researchers procuring peptides in India.
As of 2026, CDSCO has not issued specific guidelines for certain peptide product categories, such as transdermal peptide patches, creating regulatory uncertainty for developers. The government is actively considering clearer definitions for biological medicines, driven partly by the growing number of applications for synthetic and r-DNA drug products.
For research purposes, peptides are typically procured through institutional pathways. Research institutions and qualified investigators can obtain high-purity compounds for in-vitro studies by following appropriate procurement and compliance protocols.
Major Suppliers of Peptides in India
CorePeptides India
CorePeptides India is a research peptide supplier serving the scientific community across India. The company provides high-purity research peptides to academic institutions, pharmaceutical companies, and independent laboratories.
Product Catalog: CorePeptides India offers a comprehensive catalog of research-grade peptides, including BPC-157, TB-500, GHK-Cu, Semaglutide, Tirzepatide, Epitalon, CJC-1295, and more.
Quality Commitment: The company advertises purity exceeding 99%, verified by third-party laboratory testing using HPLC and mass spectrometry. Every batch comes with batch-specific Certificates of Analysis (COAs) from independent labs.
Community Reputation: CorePeptides has garnered positive feedback from the research community, with researchers praising reliable product quality, competitive pricing, and responsive customer support.
Mission: Supporting scientific progress through transparency, traceability, and quality assurance.
🔬 For laboratory research use only. Not for human consumption.
Miro Biotech
Miro Biotech is a leading peptide biotechnology company with operations in Bangalore, India, and the United States. The company supplies HPLC-verified research-grade peptides with a minimum 99% purity to research institutions across India, North America, Latin America, Europe, Africa, Asia-Pacific, and the Middle East. Their catalog includes widely studied research peptides such as Retatrutide, BPC-157, and GHK-Cu. Miro Biotech's Bangalore operations support individual researchers with INR pricing and UPI-enabled procurement. Every batch is supported by a Certificate of Analysis.
Biopeptide
Biopeptide is a research-focused peptide supplier dedicated to providing high-quality products to customers across India. The company has earned a 4.5 out of 5 rating on Trustpilot. Every batch is supported by a Certificate of Analysis (COA) and relevant lab documentation so customers can verify purity and authenticity with confidence.
HLB PEP and Bioserve
HLB PEP, a Korean company specializing in peptide-based technologies, has signed an exclusive supply agreement with Bioserve Biotechnologies in India. Under the agreement, Bioserve will import high-quality peptide raw materials produced by HLB PEP and serve as the exclusive distributor for research use across India. HLB PEP is the only company in Korea to have obtained GMP certification for peptide production. Bioserve's client base includes major Indian universities, public research institutes, and biotechnology companies.
SynZeal Peptides
SynZeal is an ISO 17025:2017 and ISO 17034:2016 accredited research-driven company specializing in the development of pharmacopeial and non-pharmacopeial reference standards. Their Certificate of Analysis includes all characterization and purity data required for regulatory compliances, with all analytical data peer-reviewed and undergoing thorough technical QC review.
Hemmo Pharmaceuticals
Hemmo Pharmaceuticals is India's first and largest manufacturer of synthetic peptides, supplying to the pharmaceutical, research, and veterinary industries within India and overseas.
Research Institutions Advancing Peptide Science in India
India's academic and research institutions are at the forefront of peptide science:
- IIT Jodhpur — Research on engineered neuro-regenerative peptide hydrogels
- CSIR-Indian Institute of Chemical Biology, Kolkata — Peptide design and structural biology
- IISER Kolkata — Research on antimicrobial peptides and peptide conjugates
- IIT Guwahati — De novo design of antimicrobial peptides
- IIT Delhi — Peptide biologics for cancer and fungal infections
- IIT Kanpur — Research on crown ether-containing peptides
- Granules India at IIT Hyderabad — Ascelis CoE for Peptide Development and Characterization
How to Evaluate Quality When Sourcing Peptides in India
When sourcing peptides in India, researchers should follow these verification steps:
1. Request and Review the COA
Ask for the COA for the specific batch you intend to order. A legitimate supplier will provide this without hesitation. Review:
- Does the COA show HPLC purity data? Look for ≥98-99%
- Does it include mass spectrometry identity confirmation?
- Is there a testing date?
- Is the testing laboratory named and verifiable?
2. Verify Business Identity
A legitimate supplier has verifiable business details: company registration, physical address, operating history, and transparent contact information.
3. Beware of Red Flags
Watch for these warning signs:
- No COA provided — a legitimate supplier provides batch-specific COAs
- Generic or undated COA — the document may not describe your batch
- No mass spectrometry data — HPLC purity alone does not confirm identity
- Impossible purity claims — consistent claims of >99% purity across all products are unrealistic
- Medical claims — any vendor claiming FDA approval for research peptides or making treatment claims is either ignorant or misleading
- Cryptocurrency-only payment — exclusive crypto payments prevent chargebacks
- No cold-chain shipping — peptides degrade without proper temperature control
Frequently Asked Questions
1. What is the current size of the peptide market in India?
The peptide therapeutics market in India generated revenue of USD 1,127.3 million in 2025 and is expected to reach USD 2,649.8 million by 2033, growing at a CAGR of 9.9%.
2. What is driving the growth of peptides in India?
Key drivers include government support through the BioE3 Policy and RDI Fund, patent expiries on GLP-1 therapies, a growing biotech startup ecosystem (over 11,800 startups), and expanding research infrastructure at institutions like IITs and IISERs.
3. How does CDSCO regulate peptides in India?
CDSCO regulates peptides under the Drugs and Cosmetics Act, 1940, and applies biologic-like scrutiny based on manufacturing complexity regardless of peptide size. As of 2026, CDSCO has not issued specific guidelines for certain peptide product categories.
4. What are the major suppliers of peptides in India?
Major suppliers include CorePeptides India, Miro Biotech, Biopeptide, HLB PEP (through Bioserve), SynZeal, and Hemmo Pharmaceuticals.
5. What research institutions in India work with peptides?
IIT Jodhpur, CSIR-IICB Kolkata, IISER Kolkata, IIT Guwahati, IIT Delhi, IIT Kanpur, and Granules India's CoE at IIT Hyderabad are among the institutions advancing peptide research in India.
6. How can I verify a peptide supplier in India?
Request a batch-specific COA, check for sealed and labelled packaging, confirm cold-chain shipping, and verify business details. Always review the COA for the specific batch you are ordering.
Final Thoughts
India has emerged as a significant player in the global peptide landscape. With a bioeconomy surpassing $195 billion, a peptide therapeutics market projected to reach $2.65 billion by 2033, and a rapidly growing research community, the country offers immense opportunities for peptide research and development.
For researchers seeking peptides in India, the options are expanding. Domestic suppliers now offer high-purity compounds with HPLC verification and batch-specific documentation. CorePeptides India stands out as a legitimate supplier with a broad catalog and commitment to quality. Miro Biotech offers Bangalore-based operations with INR pricing and UPI-enabled procurement.
The key to successful research with peptides in India is verification. Always request the batch-specific COA before purchasing. Confirm the lot number matches the vial you receive. Verify that an independent lab performed the testing. And never assume that a professional-looking website means the supplier is legitimate — verification is proven through documentation, not design.
India's research institutions are making significant contributions to the field, from neuro-regenerative peptide hydrogels at IIT Jodhpur to antimicrobial peptide research at IISER Kolkata and IIT Guwahati. With the right tools and the right suppliers, Indian researchers are well-positioned to advance our understanding of peptide science and its applications.
This article is for informational and educational purposes only. Research peptides are intended for laboratory use only and are not approved for human consumption or therapeutic use without proper authorization. Always adhere to all applicable laws, regulations, and institutional protocols when procuring and using research peptides.
Sign in to leave a comment.